
EU Approves Pierre Fabre’s BRAFTOVI Regimen for First-Line mCRC Treatment
Reducing the risk of death by 51%, the European Commission has greenlit a new targeted therapy regimen for adults with BRAFV600E-mutant metastatic colorectal cancer. The approval positions the combination of BRAFTOVI, cetuximab, and FOLFOX as the first and only targeted therapy available for these patients in a first-line setting.



























